Quantitative ICP Scan from Warwick Analytical Service
News Jul 01, 2014
Warwick Analytical Service (WAS) has introduced the Quantitative ICP-Scan, a new service that determines the levels of 67 different elements at low part per million making it ideal for analyzing unknown or suspect contamination samples.
The service is competitively priced and a great starting point in determining elemental sample composition. The 67 elements covered by this proprietary WAS ICP methodology range from Silver (Ag) through to Zirconium (Zr).
The WAS Quantitative ICP Scan Service provides information on elements present at 10-100 ppm right up to greater than 1% w/w. Measured intensities are compared to intensities of traceable standards to obtain the elemental levels in the unknown sample. Multiple wavelengths have been identified for each element to avoid errors due to the spectral interferences commonly found when using only a single analytical wavelength.
Operating in an ISO 17025 and GMP compliant environment following strict operating procedures ensures Warwick Analytical Service delivers top quality ICP data consistently.
Equipped with modern high resolution ICP instrumentation and microwave digestion equipment - Warwick Analytical Service is able to offer its ICP Quantitative Scan Service on almost any solid or liquid sample.
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE
Comments | 0 ADD COMMENT
15th Symposium on the Practical Applications of Mass Spectrometry in the Biotechnology Industry
Sep 09 - Sep 12, 2018
CE in the Biotechnology & Pharmaceutical Industries: 20th Symposium on the Practical Applications for the Analysis of Proteins, Nucleotides & Small Molecules
Sep 09 - Sep 12, 2018